ReviewMolecular biology reports2026
The Runx1-Gata2 axis: epigenetic architecture of lineage fate.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular identity is established through the precise coordination of transcription factors (TFs) and chromatin remodeling complexes that shape the epigenetic landscape. In hematopoiesis, the interaction between Runx1 and Gata2 transcription factors exemplifies the role of master TFs in direct lineage specification and self-renewal. In this review, we have consolidated recent findings on the epigenetic regulation of the master TFs of the Runx1-Gata2 axis, highlighting roles beyond their classical functions as chromatin architects. Gata2 functions as a pioneer factor that accesses closed chromatin, while Runx1 participates in reshaping topologically associating domains (TADs) and enhancer-promoter interactions, recruiting effectors such as chromodomain helicase DNA-binding protein 7 (CHD7) and ten-eleven translocation (TET) enzymes. Disruptions to this axis, including hypermethylation, enhancer hijacking, or haploinsufficiency, lead to an "epigenetic addiction" in myeloid malignancies, promoting the development of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We have discussed the recent research on emerging therapeutic strategies, such as epigenetic editing and super-enhancer targeting, which aim to restore proper chromatin architecture in malignant clones.
Indexed as
Identifiers
42801378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.